Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma

We investigated the cytolytic and mechanistic activity of anti-CD19 chimeric antigen receptor natural killer (CD19.CAR.NK92) therapy in lymphoma cell lines (diffuse large B-cell, follicular, and Burkitt lymphoma), including rituximab- and obinutuzumab-resistant cells, patient-derived cells, and a hu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2020-05, Vol.34 (5), p.1291-1304
Hauptverfasser:	Ravi, Dashnamoorthy, Sarkar, Saheli, Purvey, Sneha, Passero, Frank, Beheshti, Afshin, Chen, Ying, Mokhtar, Maisarah, David, Kevin, Konry, Tania, Evens, Andrew M.
Format:	Artikel
Sprache:	eng
Schlagworte:	13/106 13/2 13/31 38/61 38/62 631/67 692/699/67/1059/2325 96/21 Activation Animals Antigens Antigens, CD19 - immunology Antigens, CD20 - immunology Apoptosis B cells Biotechnology Burkitt's lymphoma Cancer Cancer Research Care and treatment CCL3 protein CD19 antigen CD20 antigen Cell death Cell Proliferation Cell therapy Cell- and Tissue-Based Therapy Chemokines Chimeric antigen receptors Critical Care Medicine Cytokines Cytolytic activity Endopeptidases FasL protein Hematology Humans Immunoregulation Immunotherapy, Adoptive - methods Intensive Interleukin 1 Interleukin 10 Internal Medicine Killer cells Killer Cells, Natural - immunology Kinetics Lymphocytes B Lymphoma Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - metabolism Lymphoma, Non-Hodgkin - pathology Lymphoma, Non-Hodgkin - therapy Medicine Medicine & Public Health Mice Microfluidics Monoclonal antibodies Natural killer cells Non-Hodgkin's lymphoma Non-Hodgkin's lymphomas Oncology Receptors, Chimeric Antigen - immunology Rituximab Signaling Targeted cancer therapy Therapy TOR protein Transcriptome Tumor cell lines Tumor Cells, Cultured Xenograft Model Antitumor Assays Xenografts Xenotransplantation γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!